This open-label extension booster study followed a Phase III study of 1206 adults who had received two 3.75 g doses of primary AS03A-adjuvanted or non-adjuvanted H5N1 split-virus vaccine ( A/Vietnam/1194 / 2004 ; clade 1 ) ( NCT00449670 ) .